NL-OMON25176尚未招募不适用
Phase II study of oral metformin for intravesical treatment of non- muscle-invasive bladder cancer (TROJAN)
Amsterdam UMC, AMC0 个研究点目标入组 49 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age > 18 years.
- •-Patients with primary or recurrent multiple histologically confirmed Ta or T1 (non-muscle invasive), G1 or G2 (low grade) urothelial carcinoma of the bladder with no evidence of carcinoma in situ.
- •-Patients must have at least 2 lesions but no more than 10.
- •-The resected lesions must contain detrusor muscle to confirm a Ta/T1 disease.
- •-All visible lesions must be completely removed by transurethral resection at entry to the study, except for an untouched marker lesion measuring 0.5-1.0 cm in its greatest dimension.
- •-Bimanual examination immediately following transurethral resection under anaesthesia should be carried out and no mass should be felt.
- •-Adequate renal function (creatinine <150 µmol/L and/or an eGFR >60 ml/L).
- •-Adequate liver function (bilirubin <1.5 times upper limit of normal, ALAT or ASAT <2.5 the upper limit of normal).
- •-Eligible patients must be fully informed of the investigational nature of the study and written signed informed consent must be obtained prior to any study specific investigations.
- •-Mentally, physically, and geographically able to undergo treatment and follow up.
排除标准
- •-Patients having muscle-invasive disease (stage T2 or greater) or CIS.
- •-Patients with grade 3 (high-grade) tumours.
- •-Patients with diabetes mellitus receiving metformin or having received metformin in the past 6 months.
- •-Patients who have received intravesical treatment (chemotherapy or immunotherapy) within the last 3 months.
- •-Patients that are currently receiving other anti-cancer therapy.
- •-Patients with existing urinary tract infection or recurrent severe bacterial cystitis.
- •-Patients that need to be treated with a transurethral catheter.
- •-Patients with urogenital tumours with histology other than urothelial carcinoma (i.e. squamous cell or adenocarcinoma) or with urothelial carcinoma involving the upper tract or the prostatic urethra.
- •-Patients with a history of other primary malignancy (other than squamous or basal cell skin cancers or cone biopsied CIS of the uterine cervix or prostate carcinoma treated curatively with normal PSA values at inclusion) in the last five years.
- •-Patients with active, uncontrolled impairment of the renal, hepatobiliary, cardiovascular, gastrointestinal, urogenital, neurologic or hematopoietic systems that, in the opinion of the investigator, would predispose to the development of complications from the administration of metformin.
- •-Patients who are using loop diuretics, cimetidine, ranitidine, cetirizine, trimethoprim, vandetanib, kinidine and/or HIV medication, for which no reasonable alternative is available.
- •-Women who are pregnant or lactating. Individuals of reproductive potential may not participate unless agreeing to use an effective contraceptive method for themselves and/or their sexual partner.
- •-Patients with ECOG-WHO performance status of 3 or 4.
- •-Patients with a known history of alcohol abuse.
- •-Patients with a known hypersensitivity to metformin.
- •-Patients who in the investigator's opinion, cannot comply with provisions of the protocol or do not understand the nature of the study.
研究者
相似试验
已完成
2 期
Phase II study of oral metformin for intravesical treatment of non-muscle-invasive bladder cancerbladder cancerNL-OMON56329Academisch Medisch Centrum49
招募中
2 期
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder CancerSuperficial Bladder CancerBladder CancerNCT03379909Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)49
招募中
3 期
Evaluation of the effectiveness of metformin in WOMAC index of overweight knee osteoarthritis patientsOsteoarthritis.Osteoarthritis of kneeIRCT20200522047538N2Mashhad University of Medical Sciences88
招募中
2 期
Study of effect of metformin in patients with relapsed epithelial ovarian cancerCTRI/2015/12/006454Cancer Institute WIA25
尚未招募
2 期
Metformin in the prevention of preeclampsiaPre-eclampsiapreeclampsia.IRCT20230730058975N1Esfahan University of Medical Sciences160